Since 1984, VENTANA has invested in over 100 portfolio companies.  As technology, market conditions and global relationships have changed, VENTANA has honed its investment strategey to participate in only the most highly promising areas.

VENTANA’s portfolio has remained a dynamic mix of high technology and biotech companies. Based on seeking out the most promising and disruptive technologies,VENTANA’s portfolio reflects the best technology developments in the areas of semiconductors, wireless/ communications infrastructure, biopharma and drug discovery.

The following portfolio companies represent VENTANA’s historical investment focus of investing in Semiconductors, Wireless Communications, Communications Infrastructure, BioPharma and Drug Discovery companies:

High Technology:

• Advanced Photonix, Inc.
• Aktino, Inc.
• Brooktree Corporation (Acquired by Conexant)
• California Linear Devices
• Cymer, Inc. (CYMI)
• Fidelica Microsystems, Inc.
• Innovent Systems, Inc. (Acquired by Broadcom)
• Neophotonics (NPTN)
• PairGain Tech, Inc. (Acquired by ADC Telecom)
• Pathlight Technologies (Acquired by ADIC)
• Proxima Corp. (Acquired by InFocus, Nasdaq: INFS)
• Sequoia Communications, Inc.
• Soma Networks, Inc.

Biotechnology/Biopharma:

• Alliance Pharmaceutical (ALLP)
• Agouron Pharmaceuticals, Inc. (Acquired by Pfizer)
• BioCryst Pharmaceuticals, Inc. (BCRX)
• Corvas International, Inc. (CVAS)
• GalaGen, Inc. (GGEN.OB)
• Idun Pharmaceuticals (Acquired by Pfizer)
• Integra LifeSciences Corp. (IART)
• La Jolla Pharmaceutical Company (LJPC)
• Maxim Pharmaceuticals, Inc. (MAXM)
• R-2sold to Warburg Pincus

Innovative Energy:

VENTANA's new broadly opportunistic strategy for Innovative Energy investing will seek companies with the following traits:

• Disruptive technologies and/or business models
• Revolutionary NOT evolutionary approaches and outcomes
• Early validation that is not capital intensive